Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
PHOENIX, Jan. 25, 2016 -- Insys Therapeutics, Inc. (Nasdaq:INSY) (“Insys” or “the Company”) today issued the following statement in response to misleading reports in the media regarding the practices of its Patient Services Center:
"Insys is committed to working with health care providers, insurance companies, payors, pharmacies, and most importantly, patients, to help ensure that patients have access to the Company’s breakthrough cancer pain drug, Subsys®, a product that has helped and continues to help many patients suffering from excruciating pain related to certain cancers and cancer treatments.
"As for many specialty drugs, the path patients must travel to obtain third-party payor access and reimbursement can be complex and difficult to navigate. Insys’ Patient Services Center is a group of dedicated employees who are committed to helping patients navigate this complex environment in order to access the medications that their practicing health care provider has deemed appropriate or necessary for their treatment. These support services initiate with patient consent at the time a prescription is written, and may continue according to the patient’s needs.
"Insys requires its Patient Services Center personnel undergo specific training on applicable laws and regulations and continues to strive to comply with applicable laws and regulations through its compliance policies and procedures.
"Insys rejects the recent media reports’ account of the Company’s practices as misleading and unreliable, especially in light of the biased agenda held by the individuals who made these misrepresentations."
About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets one product, Subsys® (fentanyl sublingual spray). The Company recently submitted a New Drug Application to the U.S. Food and Drug Administration for Syndros® (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.
Subsys® and Syndros® are registered trademarks of Insys Therapeutics, Inc.
Investor Contact: Lisa M. Wilson, President In-Site Communications, Inc. Phone: 212-452-2793 Email: [email protected]
